OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 mrt 2009 - 22:05
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus published Annual Report 2008 and reiterates revised strategy for 2009
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today the publication of its Annual Report 2008.
During the year 2008, OctoPlus adapted its strategy to utilise its proprietary drug delivery technology for the controlled release of injectable products, in particular proteins, on behalf of a growing client base. The main product based on this technology, Locteron®, is moving into clinical Phase IIb this year. In 2008, OctoPlus worked on five projects to evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’ proprietary drug delivery technology, and the Company aims to sign six more in 2009. Together with the anticipated growth in our Contract Development services we expect to be able to achieve a positive cashflow at the operational level for the year 2009.
The Annual Report is available on the Company’s website, www.octoplus.nl. Hard copies of the report can be requested by sending an e-mail to IR@octoplus.nl.
Datum laatste update: 19 december 2025